Experts and Doctors on ovarian neoplasms in United States

Summary

Locale: United States
Topic: ovarian neoplasms

Top Publications

  1. Rauh Adelmann C, Lau K, Sabeti N, Long J, Mok S, Ho S. Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines. Mol Carcinog. 2000;28:236-46 pubmed
    ..At present, the functionality of BRCA2 delta 12 remains elusive. ..
  2. Townsend D, Manevich Y, He L, Xiong Y, Bowers R, Hutchens S, et al. Nitrosative stress-induced s-glutathionylation of protein disulfide isomerase leads to activation of the unfolded protein response. Cancer Res. 2009;69:7626-34 pubmed publisher
    ..Thus, it appears that S-glutathionylation of PDI is an upstream signaling event in the UPR and may be linked with the cytotoxic potential of PABA/NO. ..
  3. Milam M, Tao X, Coleman R, Harrell R, Bassett R, dos Reis R, et al. Neoadjuvant chemotherapy is associated with prolonged primary treatment intervals in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2011;21:66-71 pubmed publisher
    ..In this cohort, NC was also associated with prolonged chemotherapy treatment intervals and increased chemotherapy cycles without improvement in survival. ..
  4. Sethi G, Pathak H, Zhang H, Zhou Y, Einarson M, Vathipadiekal V, et al. An RNA interference lethality screen of the human druggable genome to identify molecular vulnerabilities in epithelial ovarian cancer. PLoS ONE. 2012;7:e47086 pubmed publisher
  5. Belisle J, Gubbels J, Raphael C, Migneault M, Rancourt C, Connor J, et al. Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125). Immunology. 2007;122:418-29 pubmed
    ..Similar to EOC, MUC16 in early pregnancy also binds to NK cells suggesting shared mechanisms of NK cell suppression in feto-maternal tolerance and immune evasion by ovarian cancers. ..
  6. Arvizo R, Moyano D, Saha S, Thompson M, Bhattacharya R, Rotello V, et al. Probing novel roles of the mitochondrial uniporter in ovarian cancer cells using nanoparticles. J Biol Chem. 2013;288:17610-8 pubmed publisher
  7. Eng C, Hampel H, de la Chapelle A. Genetic testing for cancer predisposition. Annu Rev Med. 2001;52:371-400 pubmed
    ..Thorough medical care requires the identification of families likely to have a hereditary cancer susceptibility syndrome for referral to cancer genetics professionals...
  8. Varma R, Hector S, Clark K, Greco W, Hawthorn L, Pendyala L. Gene expression profiling of a clonal isolate of oxaliplatin-resistant ovarian carcinoma cell line A2780/C10. Oncol Rep. 2005;14:925-32 pubmed
    ..The identification of these genes should aid in a better understanding of the pathways resulting in platinum drug resistance. ..
  9. Batchu R, Gruzdyn O, Moreno Bost A, Szmania S, Jayandharan G, Srivastava A, et al. Efficient lysis of epithelial ovarian cancer cells by MAGE-A3-induced cytotoxic T lymphocytes using rAAV-6 capsid mutant vector. Vaccine. 2014;32:938-43 pubmed publisher
    ..This form of rAAV-based DC immunotherapy, either alone or more likely in combination with other immune-enhancing protocols, may prove useful in the clinical setting for management of EOC. ..

More Information

Publications474 found, 100 shown here

  1. Swisher E, Sakai W, Karlan B, Wurz K, Urban N, Taniguchi T. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 2008;68:2581-6 pubmed publisher
    ..Our results suggest that secondary mutations in BRCA1 can mediate resistance to platinum in BRCA1-mutated ovarian tumors. ..
  2. Rose S. Notch signaling pathway in ovarian cancer. Int J Gynecol Cancer. 2009;19:564-6 pubmed publisher
    ..I will review the evidence for Notch activation in ovarian cancer and potential strategies for Notch inactivation as targeted treatment of ovarian cancer. ..
  3. Milam M, Harrell R, Bassett R, Parker L, Metzinger D, Ramirez P. Clinical characteristics of patients with prolonged disease-free survival after primary treatment in advanced ovarian cancer: a brief report. Int J Gynecol Cancer. 2011;21:475-7 pubmed publisher
    ..Further study is needed in patient and tumor characteristics to identify those patients who may have poor or favorable outcomes before treatment completion. ..
  4. Rose S, Spencer R, Rausch M. The use of humor in patients with recurrent ovarian cancer: a phenomenological study. Int J Gynecol Cancer. 2013;23:775-9 pubmed publisher
    ..The waiting area seems to be a place where humorous experiences would be welcomed. These findings provide additional insight into the role that humor plays in the lives of patients with recurrent ovarian cancer. ..
  5. Ramos P, Karnezis A, Craig D, Sekulic A, Russell M, Hendricks W, et al. Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. Nat Genet. 2014;46:427-9 pubmed publisher
    ..4% (2/485) of other primary ovarian tumors. These data implicate SMARCA4 in SCCOHT oncogenesis. ..
  6. Peterlongo P, Chang Claude J, Moysich K, Rudolph A, Schmutzler R, Simard J, et al. Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2015;24:308-16 pubmed publisher
    ..Genome-wide association studies have been more successful at identifying genetic modifiers of BRCA1/2 penetrance than candidate gene studies. ..
  7. Landen C, Mathur S, Richardson M, Creasman W. Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignancies. Am J Obstet Gynecol. 2003;188:1174-6 pubmed
    ..001). In this cohort, COX-2 expression is significantly more common in endometrial adenocarcinoma and ovarian serous cystadenocarcinoma, but not in cervical squamous carcinoma, compared with normal tissue. ..
  8. Tate Thigpen J, Blessing J, Degeest K, Look K, Homesley H. Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;93:336-9 pubmed
    ..These data provide the first objective evidence that cisplatin is active as an initial therapy for patients who have carcinosarcoma of the ovary. The overall response rate (20%) is similar to that seen in carcinosarcomas of the uterus. ..
  9. Pantanowitz L, Otis C, Goulart R. Cytologic findings of psammocarcinoma in peritoneal washings. Acta Cytol. 2009;53:263-7 pubmed
  10. Rodzinski A, Guduru R, Liang P, Hadjikhani A, Stewart T, Stimphil E, et al. Targeted and controlled anticancer drug delivery and release with magnetoelectric nanoparticles. Sci Rep. 2016;6:20867 pubmed publisher
  11. Markman M, Webster K, Zanotti K, Peterson G, Kulp B, Belinson J. Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials. Gynecol Oncol. 2004;93:699-701 pubmed
    ..It remains uncertain whether such unexpectedly prolonged survival results from a biological response to chemotherapy or simply reflects the natural history of disease in a subset of patients with this malignancy. ..
  12. Martorell E, Murray P, Peterson J, Menke D, Calamia K. Palmar fasciitis and arthritis syndrome associated with metastatic ovarian carcinoma: a report of four cases. J Hand Surg Am. 2004;29:654-60 pubmed
    ..Digital contractures, however, can persist. We recommend a gynecologic examination in any woman presenting with the sudden onset of unexplained hand pain, palmar inflammatory fasciitis, palmar fibromatosis, and digital contractures...
  13. Ren J, Xiao Y, Singh L, Zhao X, Zhao Z, Feng L, et al. Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells. Cancer Res. 2006;66:3006-14 pubmed
    ..Conditioned medium from peritoneal mesothelial cells stimulate migration, adhesion, and invasion of ovarian cancer cells, and may play similar roles in vivo. ..
  14. Gubbels J, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, et al. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer. 2006;5:50 pubmed
    ..The demonstration that N-linked glycans are essential for mediating mesothlein-MUC16 binding may lead to novel therapeutic targets to control the spread of ovarian carcinoma. ..
  15. Krivak T, Tian C, Rose G, Armstrong D, Maxwell G. A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: an analysis of patients enrolled in GOG 172. Gynecol Oncol. 2009;115:81-85 pubmed publisher
    ..Serum CA-125 algorithms for monitoring treatment effect that have been established for IV chemotherapy may also be applied for patients receiving IP chemotherapy. ..
  16. Chegini N, Zhao Y, McLean F. Expression of messenger ribonucleic acid and presence of immunoreactive proteins for epidermal growth factor (EGF), transforming growth factor alpha (TGF alpha) and EGF/TGF alpha receptors and 125I-EGF binding sites in human fallopian tube. Biol Reprod. 1994;50:1049-58 pubmed
    ..The results imply the importance of EGF/TGF alpha in a variety of tubal biochemical and physiological functions and possibly early embryonic development. ..
  17. Gercel Taylor C, Bazzett L, Taylor D. Presence of aberrant tumor-reactive immunoglobulins in the circulation of patients with ovarian cancer. Gynecol Oncol. 2001;81:71-6 pubmed
    ..This altered IgG appeared to be the primary class of tumor-reactive antibodies in these women. ..
  18. Desouki M, Kulawiec M, Bansal S, Das G, Singh K. Cross talk between mitochondria and superoxide generating NADPH oxidase in breast and ovarian tumors. Cancer Biol Ther. 2005;4:1367-73 pubmed
    ..Furthermore, our studies suggest that mitochondria control Nox1 redox signaling and the loss of control of this signaling contributes to breast and ovarian tumorigenesis. ..
  19. Wyman S, Parkin R, Mitchell P, Fritz B, O Briant K, Godwin A, et al. Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS ONE. 2009;4:e5311 pubmed publisher
    ..This report expands the body of miRNAs known to be expressed in epithelial ovarian cancer and provides a useful resource for future studies of the role of miRNAs in the pathogenesis and early detection of ovarian cancer. ..
  20. Dworkin A, Spearman A, Tseng S, Sweet K, Toland A. Methylation not a frequent "second hit" in tumors with germline BRCA mutations. Fam Cancer. 2009;8:339-46 pubmed publisher
    ..Of these, only one tumor with a BRCA2 mutation showed promoter methylation. These data indicate that promoter methylation is a not a frequent "second-hit" in tumors from BRCA1 or BRCA2 carriers. ..
  21. O Malley D, Richardson D, Rheaume P, Salani R, Eisenhauer E, McCann G, et al. Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. Gynecol Oncol. 2011;121:269-72 pubmed publisher
    ..This data should be helpful in guiding future trials to determine the optimal care for women with recurrent EOC. ..
  22. Bradley A, Zheng H, Ziebarth A, Sakati W, Branham O Connor M, Blumer J, et al. EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer. Carcinogenesis. 2014;35:1100-9 pubmed publisher
    ..4% reduction, P = 0.035), with a trend in A2780ip2 (60.3% reduction, P = 0.168). These results identify EDD as a dual regulator of cell survival and cisplatin resistance and suggest that EDD is a therapeutic target for ovarian cancer. ..
  23. Weekes C, Lamberts L, Borad M, Voortman J, McWilliams R, Diamond J, et al. Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer. Mol Cancer Ther. 2016;15:439-47 pubmed publisher
    ..4 to 2.8 mg/kg i.v. q3w. DMOT4039A administered at doses up to 2.4 mg/kg q3w and 1.0 mg/kg weekly has a tolerable safety profile and antitumor activity in both pancreatic and ovarian cancer. ..
  24. Gao Y, Rankin G, Tu Y, Chen Y. Inhibitory Effects of the Four Main Theaflavin Derivatives Found in Black Tea on Ovarian Cancer Cells. Anticancer Res. 2016;36:643-51 pubmed
    ..All four theaflavin derivatives inhibited ovarian cancer cells. Some of the effects and mechanisms of TF1 are different from those of the other three theaflavin derivatives. ..
  25. Johannesdottir S, Schmidt M, Phillips G, Glaser R, Yang E, Blumenfeld M, et al. Use of ß-blockers and mortality following ovarian cancer diagnosis: a population-based cohort study. BMC Cancer. 2013;13:85 pubmed publisher
    ..Secondary analyses stratifying by cancer stage and duration of ß-blocker use supported the overall results. We found no evidence that ß-blocker use was associated with decreased mortality following ovarian cancer diagnosis. ..
  26. Qin B, Moorman P, Alberg A, Barnholtz Sloan J, Bondy M, Cote M, et al. Dietary carbohydrate intake, glycaemic load, glycaemic index and ovarian cancer risk in African-American women. Br J Nutr. 2016;115:694-702 pubmed publisher
    ..No associations were observed for starch or GI. Our findings suggest that high intake of total sugars and GL are associated with greater risk of ovarian cancer in African-American women. ..
  27. Kaneko S, Gerasimova T, Smith S, Lloyd K, Suzumori K, Young S. CA125 and UQCRFS1 FISH studies of ovarian carcinoma. Gynecol Oncol. 2003;90:29-36 pubmed
    ..Unexpectedly, the UQCRFS1 region was also sometimes amplified as HSRs. The UQCRFS1 protein is also known as complex III of the mitochondrial respiratory chain. This product may have an important role in malignant cells. ..
  28. Matei D, Fang F, Shen C, Schilder J, Arnold A, Zeng Y, et al. Epigenetic resensitization to platinum in ovarian cancer. Cancer Res. 2012;72:2197-205 pubmed publisher
  29. Flessner M, Choi J, Credit K, Deverkadra R, Henderson K. Resistance of tumor interstitial pressure to the penetration of intraperitoneally delivered antibodies into metastatic ovarian tumors. Clin Cancer Res. 2005;11:3117-25 pubmed
    ..The results only partially support our hypothesis and imply that the microenvironment of the tumor is in itself a major barrier to delivery of charged macromolecules. ..
  30. Godoy H, Mhawech Fauceglia P, Beck A, Miller A, Lele S, Odunsi K. Expression of poly (adenosine diphosphate-ribose) polymerase and p53 in epithelial ovarian cancer and their role in prognosis and disease outcome. Int J Gynecol Pathol. 2011;30:139-44 pubmed publisher
    ..Additional studies are warranted to evaluate the role of PARP and PARP inhibitors in the setting of adjuvant chemotherapy. ..
  31. Candido dos Reis F, Song H, Goode E, Cunningham J, Fridley B, Larson M, et al. Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer. Clin Cancer Res. 2015;21:652-7 pubmed publisher
    ..This may have important implications for therapy of both primary and relapsed disease and for analysis of long-term survival in clinical trials of new agents, particularly those that are effective in BRCA1/2 mutation carriers. ..
  32. Despierre E, Vergote I, Anderson R, Coens C, Katsaros D, Hirsch F, et al. Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy. Target Oncol. 2015;10:583-96 pubmed publisher
    ..In this phase III study, increased EGFR gene copy number was associated with worse OS and PFS in patients with ovarian cancer. It remains to be determined whether this association is purely prognostic or is also predictive. ..
  33. Lu J, Xiao Yj Y, Baudhuin L, Hong G, Xu Y. Role of ether-linked lysophosphatidic acids in ovarian cancer cells. J Lipid Res. 2002;43:463-76 pubmed
    ..On the other hand, cell migration induced by al-LPAs depended on activities of the G(i/o) protein, PI3K, and Rho, but not MEK. These data suggest that ether-linked LPAs may play an important role in ovarian cancer development. ..
  34. Peng K, Teneyck C, Galanis E, Kalli K, Hartmann L, Russell S. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res. 2002;62:4656-62 pubmed
    ..Trackable recombinant measles viruses warrant further investigation for therapy of ovarian cancer. ..
  35. Sweet K, Senter L, Pilarski R, Wei L, Toland A. Characterization of BRCA1 ring finger variants of uncertain significance. Breast Cancer Res Treat. 2010;119:737-43 pubmed publisher
    ..Two variants, L22S and T37K, were predicted to be deleterious and one variant, K45Q, was predicted to be neutral by VUS Predict. The mutations C39R, C44Y, C44S, and C61G were confirmed as deleterious. ..
  36. Peres L, Camacho F, Abbott S, Alberg A, Bandera E, Barnholtz Sloan J, et al. Analgesic medication use and risk of epithelial ovarian cancer in African American women. Br J Cancer. 2016;114:819-25 pubmed publisher
    ..No association was observed for acetaminophen use. Collectively, these findings support previous evidence that any NSAID use is inversely associated with EOC risk. ..
  37. Bhattacharya R, Nicoloso M, Arvizo R, Wang E, Cortez A, Rossi S, et al. MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. Cancer Res. 2009;69:9090-5 pubmed publisher
    ..These findings suggest the development of therapeutic strategies by restoring miR-15a and miR-16 expression in ovarian cancer and in other cancers that involve upregulation of Bmi-1. ..
  38. Wang B, Kaumaya P, Cohn D. Immunization with synthetic VEGF peptides in ovarian cancer. Gynecol Oncol. 2010;119:564-70 pubmed publisher
    ..Active immunization with VEGF peptides elicits antibodies that inhibit tumor growth by blocking VEGF-dependent angiogenesis. ..
  39. Backes F, Richardson D, McCann G, Smith B, Salani R, Eisenhauer E, et al. Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?. Int J Gynecol Cancer. 2013;23:833-8 pubmed publisher
    ..The response to the first Bev regimen did not predict whether a patient would respond again to the next Bev regimen. Randomized, larger studies will have to be performed to confirm this observation. ..
  40. Vergote I, Garcia A, Micha J, Pippitt C, Bendell J, Spitz D, et al. Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer. J Clin Oncol. 2013;31:4060-6 pubmed publisher
    ..These findings provide support to directly compare etirinotecan pegol versus one of the approved drugs (eg, pegylated liposomal doxorubicin or topotecan) in platinum-resistant ovarian cancer. ..
  41. Bahleda R, Grilley Olson J, Govindan R, Barlesi F, Greillier L, Perol M, et al. Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies. Br J Cancer. 2017;116:1505-1512 pubmed publisher
    ..4% for patients with SCLC (n=33), and 33.3% for patients with CDK-related tumour mutations (n=6). Roniciclib demonstrated an acceptable safety profile and moderate DCR in 3 days on/4 days off schedule. ..
  42. Thaker P, Brady W, Lankes H, Odunsi K, Bradley W, Moore K, et al. A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary perit. Gynecol Oncol. 2017;147:283-290 pubmed publisher
    ..GEN-1 in combination with PLD has encouraging clinical benefit and biological activity in recurrent or persistent EOC and warrants further investigation with escalating doses of GEN-1. ..
  43. Li M, Naidu P, Yu Y, Berger N, Kannan P. Dual regulation of AP-2alpha transcriptional activation by poly(ADP-ribose) polymerase-1. Biochem J. 2004;382:323-9 pubmed
    ..We hypothesize that PARP-1 enhances the transcriptional activity of AP-2alpha in normal circumstances, whereas its enzymic activity is used as a temporary shut-off mechanism during unfavourable conditions. ..
  44. Scarlett U, Cubillos Ruiz J, Nesbeth Y, Martinez D, Engle X, Gewirtz A, et al. In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. Cancer Res. 2009;69:7329-37 pubmed publisher
    ..Combined administration of synergistic CD40 and TLR3 agonists could enhance their individual therapeutic effects against ovarian and other lethal epithelial cancers. ..
  45. Chang S, Guo J, Sun J, Zhu S, Yan Y, Zhu Y, et al. Targeted microbubbles for ultrasound mediated gene transfection and apoptosis induction in ovarian cancer cells. Ultrason Sonochem. 2013;20:171-179 pubmed publisher
    ..05). Our experiment verifies the hypothesis that ultrasound mediation of targeted microbubbles will enhance the gene transfection efficiency in ovarian cancer cells. ..
  46. Quill T, Back A, Block S. Responding to Patients Requesting Physician-Assisted Death: Physician Involvement at the Very End of Life. JAMA. 2016;315:245-6 pubmed publisher
  47. Bixel K, Saini U, Kumar Bid H, Fowler J, Riley M, Wanner R, et al. Targeting STAT3 by HO3867 induces apoptosis in ovarian clear cell carcinoma. Int J Cancer. 2017;141:1856-1866 pubmed publisher
    ..Inhibition of pSTAT3 using HO-3867in OCCC cell lines appears to be a promising therapy. This is of utmost importance given the poor response of OCCC to standard chemotherapy regimens. ..
  48. Odunsi K, Jungbluth A, Stockert E, Qian F, Gnjatic S, Tammela J, et al. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res. 2003;63:6076-83 pubmed
    ..These findings indicate that NY-ESO-1 and LAGE-1 are attractive targets for antigen-specific immunotherapy in EOC. ..
  49. Helm C, Richard S, Pan J, Bartlett D, Goodman M, Hoefer R, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first report of the HYPER-O registry. Int J Gynecol Cancer. 2010;20:61-9 pubmed publisher
    ..021). Hyperthermic intraperitoneal chemotherapy is a viable additional treatment option for patients with invasive EOC and may extend life in selected groups. It warrants further study in randomized controlled trials. ..
  50. Kebria M, Belinson J, Kim R, Mekhail T. Malignant acanthosis nigricans, tripe palms and the sign of Leser-Tre'lat, a hint to the diagnosis of early stage ovarian cancer: a case report and review of the literature. Gynecol Oncol. 2006;101:353-5 pubmed
  51. Petrocca F, Iliopoulos D, Qin H, Nicoloso M, Yendamuri S, Wojcik S, et al. Alterations of the tumor suppressor gene ARLTS1 in ovarian cancer. Cancer Res. 2006;66:10287-91 pubmed
  52. Rose S, Kunnimalaiyaan M, Drenzek J, Seiler N. Notch 1 signaling is active in ovarian cancer. Gynecol Oncol. 2010;117:130-3 pubmed publisher
    ..These findings support the hypothesis that Notch 1 plays a role in ovarian cancer proliferation, encouraging the investigation of this pathway as a therapeutic target. ..
  53. Flessner M, Choi J, He Z, Credit K. Physiological characterization of human ovarian cancer cells in a rat model of intraperitoneal antineoplastic therapy. J Appl Physiol (1985). 2004;97:1518-26 pubmed
    ..In conclusion, we have characterized physical and chemical parameters that determine transport of therapeutic agents in our unique tumor-bearing rat model. ..
  54. Abeysinghe H, Li L, Guckert N, Reeder J, Wang N. THY-1 induction is associated with up-regulation of fibronectin and thrombospondin-1 in human ovarian cancer. Cancer Genet Cytogenet. 2005;161:151-8 pubmed
    ..This study supports the hypothesis that THY-1 plays a critical role in regulating downstream genes associated with the regulation of ovarian tumor growth and cellular differentiation. ..
  55. Bhattacharya R, Kwon J, Ali B, Wang E, Patra S, Shridhar V, et al. Role of hedgehog signaling in ovarian cancer. Clin Cancer Res. 2008;14:7659-66 pubmed publisher
    ..Because the HH pathway can be inhibited by specific inhibitors, these findings point toward possible new treatments to inhibit ovarian cancer growth. ..
  56. Cubillos Ruiz J, Engle X, Scarlett U, Martinez D, Barber A, Elgueta R, et al. Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J Clin Invest. 2009;119:2231-44 pubmed publisher
  57. Arafa E, Zhu Q, Barakat B, Wani G, Zhao Q, El Mahdy M, et al. Tangeretin sensitizes cisplatin-resistant human ovarian cancer cells through downregulation of phosphoinositide 3-kinase/Akt signaling pathway. Cancer Res. 2009;69:8910-7 pubmed publisher
    ..Thus, effectiveness of tangeretin combinations, as a promising modality in the treatment of resistant cancers, warrants systematic clinical studies. ..
  58. Meng F, Sun G, Zhong M, Yu Y, Brewer M. Inhibition of DNA methyltransferases, histone deacetylases and lysine-specific demethylase-1 suppresses the tumorigenicity of the ovarian cancer ascites cell line SKOV3. Int J Oncol. 2013;43:495-502 pubmed publisher
  59. Yew K, Crow J, Hirst J, Pessetto Z, Pressetto Z, Godwin A. Epimorphin-induced MET sensitizes ovarian cancer cells to platinum. PLoS ONE. 2013;8:e72637 pubmed publisher
    ..Overall, we demonstrate that epimorphin can revert OCCs away from their mesenchymal phenotype and toward an epithelial phenotype, thereby enhancing their sensitivity to a front-line chemotherapeutic agent. ..
  60. Tung N, Lin N, Kidd J, Allen B, Singh N, Wenstrup R, et al. Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. J Clin Oncol. 2016;34:1460-8 pubmed publisher
    ..Additional cohorts will be helpful to define individuals at higher risk of carrying mutations in genes other than BRCA1/2. ..
  61. Eng K, Morrell K, Starbuck K, Spring Robinson C, Khan A, Cleason D, et al. Prognostic value of miliary versus non-miliary sub-staging in advanced ovarian cancer. Gynecol Oncol. 2017;146:52-57 pubmed publisher
    ..These findings should permit further retrospective investigation in a wider cohort and prompt the consideration of prospective structured operative reporting standards and treatment strategies. ..
  62. Ghadersohi A, Odunsi K, Lele S, Collins Y, Greco W, Winston J, et al. Prostate derived Ets transcription factor shows better tumor-association than other cancer-associated molecules. Oncol Rep. 2004;11:453-8 pubmed
    ..These data together show a better tumor-association for PDEF and suggest that PDEF is a more suitable target for developing specific cancer therapies. ..
  63. Narita K, Staub J, Chien J, Meyer K, Bauer M, Friedl A, et al. HSulf-1 inhibits angiogenesis and tumorigenesis in vivo. Cancer Res. 2006;66:6025-32 pubmed
    ..Collectively, these observations provide the first evidence of a novel mechanism by which HSulf-1 modulates the function of heparan sulfate binding VEGF165 in proliferation and angiogenesis. ..
  64. Hsieh F, Tengstrand E, Lee J, Li L, Silverman L, Riordan B, et al. Drug safety evaluation through biomarker analysis--a toxicity study in the cynomolgus monkey using an antibody-cytotoxic conjugate against ovarian cancer. Toxicol Appl Pharmacol. 2007;224:12-8 pubmed
    ..The safety of three different MLN8866 dosing regimens with three dosing schedules was explored with pharmacokinetic modeling. ..
  65. Tummala R, Diegelman P, Fiuza S, Batista de Carvalho L, Marques M, Kramer D, et al. Characterization of Pt-, Pd-spermine complexes for their effect on polyamine pathway and cisplatin resistance in A2780 ovarian carcinoma cells. Oncol Rep. 2010;24:15-24 pubmed
    ..These studies suggest that Pd (II)-polyamine complexes may constitute a promising group of inorganic compounds for further studies in the development of novel chemotherapy/adjuvant chemotherapy strategies. ..
  66. Alhilli M, Long H, Podratz K, Bakkum Gamez J. Aromatase inhibitors in the treatment of recurrent ovarian granulosa cell tumors: brief report and review of the literature. J Obstet Gynaecol Res. 2012;38:340-4 pubmed publisher
    ..We present a heavily pre-treated, multi-operated patient who experienced significant tumor shrinkage following treatment with an aromatase inhibitor for her recurrent granulosa cell tumor. ..
  67. Godoy H, Khan A, Vethanayagam R, Grimm M, Singel K, Kolomeyevskaya N, et al. Myeloid-derived suppressor cells modulate immune responses independently of NADPH oxidase in the ovarian tumor microenvironment in mice. PLoS ONE. 2013;8:e69631 pubmed publisher
    ..We speculate that factors inherent to the tumor, tumor microenvironment, or both determine the specific requirement for NADPH oxidase in MDSC accumulation and function. ..
  68. Ripley D, Tunuguntla R, Susi L, Chegini N. Expression of matrix metalloproteinase-26 and tissue inhibitors of metalloproteinase-3 and -4 in normal ovary and ovarian carcinoma. Int J Gynecol Cancer. 2006;16:1794-800 pubmed
    ..MMP-26, TIMP-3, and TIMP-4 are expressed in normal ovarian as well as ovarian tumors with elevated expression in the invasive tumor cells suggesting a potential role for MMP-26 in normal ovary and ovarian cancer biologic function. ..
  69. Li Y, Ganta S, Cheng C, Craig R, Ganta R, Freeman L. FSH stimulates ovarian cancer cell growth by action on growth factor variant receptor. Mol Cell Endocrinol. 2007;267:26-37 pubmed
    ..9kb transcript. Immunoblot analysis confirmed expression of FSH-R3 but not FSHR-1 in ID8. Together, these data suggest that FSH-R3 signaling promotes proliferation of ovarian cancer cells. ..
  70. Ahmad N, Kumar R. Steroid hormone receptors in cancer development: a target for cancer therapeutics. Cancer Lett. 2011;300:1-9 pubmed publisher
    ..In this review article, we have summarized up-to-date knowledge of the role of SHRs in the development and progression of cancers, and potential endocrine-based therapeutic approaches to tackle these diseases. ..
  71. Beland F, Mellick P, Olson G, Mendoza M, Marques M, Doerge D. Carcinogenicity of acrylamide in B6C3F(1) mice and F344/N rats from a 2-year drinking water exposure. Food Chem Toxicol. 2013;51:149-59 pubmed publisher
    ..These results, combined with previous mechanistic studies, provide strong support for the concept that acrylamide is activated to a carcinogen through metabolism to glycidamide...
  72. DeHaven K, Taylor D, Gercel Taylor C. Comparison of serum vascular endothelial growth levels between patients with and without ovarian malignancies. Int J Gynecol Cancer. 2002;12:715-9 pubmed
    ..Based on our data, due to the lack of significant difference in mean serum VEGF values between patients with and without ovarian malignancies, we feel that serum VEGF cannot be used as a possible screening tool for ovarian cancer. ..
  73. Shamshirsaz A, Withiam Leitch M, Odunsi K, Baker T, Frederick P, Lele S. Young patients with endometrial carcinoma selected for conservative treatment: a need for vigilance for synchronous ovarian carcinomas, case report and literature review. Gynecol Oncol. 2007;104:757-60 pubmed
    ..Those who desire ovarian preservation should be counseled regarding the high potential for coexisting ovarian malignancy. ..
  74. Fader A, von Gruenigen V, Gibbons H, Abushahin F, Starks D, Markman M, et al. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients. Gynecol Oncol. 2008;109:33-8 pubmed publisher
    ..Age, performance status and other geriatric parameters should be considered when dosing chemotherapy in the elderly. ..
  75. Lin F, Shi J, Liu H, Zhang J, Zhang P, Wang H, et al. Immunohistochemical detection of the von Hippel-Lindau gene product (pVHL) in human tissues and tumors: a useful marker for metastatic renal cell carcinoma and clear cell carcinoma of the ovary and uterus. Am J Clin Pathol. 2008;129:592-605 pubmed publisher
    ..These data indicate that this anti-pVHL antibody is a useful marker in assisting diagnosis of metastatic RCC and may serve as a diagnostic marker for clear cell carcinomas of the ovary and uterus. ..
  76. Faca V, Ventura A, Fitzgibbon M, Pereira Faca S, Pitteri S, Green A, et al. Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains. PLoS ONE. 2008;3:e2425 pubmed publisher
    ..Cell surface and secreted proteins identified by in-depth proteomic profiling of ovarian cancer cells may provide new targets for diagnosis and therapy. ..
  77. Chen L, Xuan J, Wang C, Shih I, Wang Y, Zhang Z, et al. Knowledge-guided multi-scale independent component analysis for biomarker identification. BMC Bioinformatics. 2008;9:416 pubmed publisher
    ..More importantly, the proposed approach shows promising results to infer novel biomarkers for ovarian cancer and extend current knowledge. ..
  78. Blair A, Casas C. Gynecologic cancers. Prim Care. 2009;36:115-30, ix pubmed publisher
    ..In this article, the epidemiology, screening guidelines, and a review of management are presented for vulvar, cervical, ovarian, and endometrial cancer. ..
  79. Sehdev A, Kurman R, Kuhn E, Shih I. Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase. Mod Pathol. 2010;23:844-55 pubmed publisher
    ..In contrast, mucin-4 immunoreactivity either did not change or was reduced in most STICs. These results suggest that overexpression of Rsf-1, cyclin E and FASN occurs early in tumor progression. ..
  80. Rice L. Hormone prevention strategies for breast, endometrial and ovarian cancers. Gynecol Oncol. 2010;118:202-7 pubmed publisher
    ..Prospective, randomized trials, designed to control for all known variables, are mandatory to fully assess the potential for hormonal chemoprevention in breast, endometrial and ovarian cancers. ..
  81. Shah P, Kakar S. Pituitary tumor transforming gene induces epithelial to mesenchymal transition by regulation of Twist, Snail, Slug, and E-cadherin. Cancer Lett. 2011;311:66-76 pubmed publisher
    ..In contrast reverse phenomena was observed on depletion of PTTG on infection of cells with Ad-PTTG siRNA, suggesting an important role of PTTG in induction of EMT in ovarian cancer cells. ..
  82. Xiao W, Awadallah A, Xin W. Loss of ARID1A/BAF250a expression in ovarian endometriosis and clear cell carcinoma. Int J Clin Exp Pathol. 2012;5:642-50 pubmed
    ..These data suggest that a portion of benign ovarian endometriosis has already undergone genetic alterations that lead to aberrant protein expression, possibly conferring a higher risk for malignant transformation. ..
  83. Nourani M, Manera R. Pediatric ovarian dysgerminoma presenting with hypercalcemia and chronic constipation: a case report. J Pediatr Hematol Oncol. 2013;35:e272-3 pubmed publisher
    ..We review some of the causes of malignancy-associated hypercalcemia described in literature and treatment strategies. We also recommend considering oncological processes in the presence of hypercalcemia. ..
  84. Shah N, Tancioni I, Ward K, Lawson C, Chen X, Jean C, et al. Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer. Gynecol Oncol. 2014;134:104-11 pubmed publisher
    ..Merlin levels may be useful for patient stratification in FAK inhibitor trials. ..
  85. Oliver K, Brady W, Birrer M, Gershenson D, Fleming G, Copeland L, et al. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. Gynecol Oncol. 2017;147:243-249 pubmed publisher
    ..Finally, treatment effect was influenced by histology. ..
  86. Shen Z, Wu M, Elson P, Kennedy A, Belinson J, Casey G, et al. Fatty acid composition of lysophosphatidic acid and lysophosphatidylinositol in plasma from patients with ovarian cancer and other gynecological diseases. Gynecol Oncol. 2001;83:25-30 pubmed
    ..However, our results suggest that increased LPA/LPI species with unsaturated fatty acid chains may be associated with late-stage or recurrent ovarian cancer. ..
  87. Hylander B, Repasky E, Shrikant P, Intengan M, Beck A, Driscoll D, et al. Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer. Gynecol Oncol. 2006;101:12-7 pubmed
    ..Since WT1 demonstrates tissue-restricted expression and is inherently immunogenic, it could represent an attractive target for antigen-specific immunotherapy in EOC. ..
  88. Scholler N, Crawford M, Sato A, Drescher C, O Briant K, Kiviat N, et al. Bead-based ELISA for validation of ovarian cancer early detection markers. Clin Cancer Res. 2006;12:2117-24 pubmed
  89. Peluso J, Liu X, Saunders M, Claffey K, Phoenix K. Regulation of ovarian cancer cell viability and sensitivity to cisplatin by progesterone receptor membrane component-1. J Clin Endocrinol Metab. 2008;93:1592-9 pubmed publisher
    ..These data suggest that targeted depletion of PGRMC1 could be useful as an adjunct to CDDP therapy. ..
  90. Bedaiwy M, Hussein M, Biscotti C, Falcone T. Pelvic endometriosis is rarely associated with ovarian borderline tumours, cytologic and architectural atypia: a clinicopathologic study. Pathol Oncol Res. 2009;15:81-8 pubmed publisher
    ..Our findings recommend surgical excision of these foci rather than their simple cauterization...
  91. Tan W, Stehman F, Carter R. Mortality rates due to gynecologic cancers in New York state by demographic factors and proximity to a Gynecologic Oncology Group member treatment center: 1979-2001. Gynecol Oncol. 2009;114:346-52 pubmed publisher
  92. Liu B, Nash J, Runowicz C, Swede H, Stevens R, Li Z. Ovarian cancer immunotherapy: opportunities, progresses and challenges. J Hematol Oncol. 2010;3:7 pubmed publisher
    ..Finally, we will summarize our own experience on the use of patient-specific tumor-derived heat shock protein-peptide complex for the treatment of advanced ovarian cancer. ..